European Psychiatry - Volume 33 - March 2016

320 / 812

S316 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
of the negative symptoms domains might help refining hypotheses
on their pathophysiological basis.
Aims The objective of this study was to evaluate, in the con-
text of the multicenter study of the Italian Network for Research
on Psychoses, the relationships between auditory event-related
potentials (ERPs) components and negative symptom domains in
patients with schizophrenia (SCZ).
Methods We examined ERPs recorded during an auditory odd-
ball task in 115 chronic stabilized SCZ (78% on second-generation
antipsychotics) and 62 matched healthy controls (HC). Negative
symptoms were assessed using the Brief Negative Symptom Scale.
Results Our main findings included significant N100 and P3b
amplitude reductions in SCZ compared toHC. P3b amplitude didnot
correlate with any negative symptom domain, while N100 ampli-
tude correlated with both anhedonia and avolition domains.
Conclusions Avolition and anhedonia, often clustering in the
same factor, are related to abnormalities of early components of
the ERPs correlated with perceptual and automatic attention pro-
cesses. None of the negative symptom domains is associated with
abnormalities of the later stages indexed by P3 amplitude.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW570
Self-Stigma and adherence to
medication in patients with psychotic
disorders – cross-sectional study
K. Vrbova ∗, D. Kamaradova , K. Latalova , M. Ociskova , J. Prasko ,
B. Mainerova , A. Cinculova , R. Kubinek , A. Tichackova
Faculty of Medicine and Dentistry- Palacky University Olomouc and
University Hos, Department of Psychiatry, Olomouc, Czech Republic
∗ Corresponding author.
Introduction Adherence to treatment of mental disorders is one
of the key factors influencing its success and, secondarily, the
patients’ quality of life and social adaptation.
Aims The cross-sectional study of 90 outpatients diagnosed with
psychotic disorders aimed at determining if there was a relation-
ship between discontinuation of medication in the past, current
adherence to treatment and self-stigma.
Methods The assessment was made with the objective and sub-
jective Clinical Global Impression – Severity scale, Drug Attitude
Inventory, Internalized Stigma of Mental Illness (ISMI) scale and
demographic data.
Results The questionnaires were filled out by 79 patients, of
whom 5 handed in incomplete questionnaires. Complete sets of
data were obtained from 74 patients. The data analysis showed
that the levels of self-stigma as assessed by the total ISMI scores
was not statistically significantly correlatedwithmost of the demo-
graphic factors (age, age of illness onset, gender, education, marital
status, employment, duration of the illness, number of hospitaliza-
tions and antipsychotic dosage). However, there was a significant
negative correlation with current adherence to treatment.
Conclusions Adherence to treatment is one of the most impor-
tant prerequisites for successful therapy. Adherence may be
enhanced through better motivation and education of patients
on the necessity of adhering to treatment recommendations and
the consequences of non-adherent behavior. Important factors in
adherence also seem to be patients’ stigmatization and self-stigma.
Adherence may be increased by promising self-stigma-reducing
strategies performed by systematic psychoeducation of patients or
as a part of psychotherapeutic counseling.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW571
Healthcare resource use of
paliperidone palmitate 3-month
injection vs. paliperidone palmitate
1-month injection: An analysis of
phase III clinical trial hospital data
K. Woodruff ∗, C. Chirila , Q. Zheng , K. Van Impe , I. Nuamah
1 Janssen Research & Development - LLC, Global Market Access,
Titusville, USA
2 RTI-Health Solutions, Biostatistics, Research Triangle Park, USA
3 Janssen-Cilag, Market Access, North Brabant, Netherlands
4 Janssen Research & Development - LLC, Biostatistics, Titusville, USA
∗ Corresponding author.
Introduction PSY-3011 was a randomized, multicenter, double-
blind, non-inferiority study of paliperidone palmitate 3-month
injection (PP3M) vs. paliperidone palmitate 1-month injection
(PP1M). Adults with schizophrenia were stabilized on PP1M in an
open-label (OL) 17-week transition phase. Qualifying subjects at
the end of the OL phase were then randomized to PP3M or PP1M
in the 48-week double-blind (DB) phase. Healthcare resource uti-
lization (HCRU) between PP3M and PP1M was compared using the
HCRU questionnaire during the double-blind (DB) phase.
Methods HCRU was measured at the start of the OL and DB
phases, and every 12 weeks during DB until end of study/early
withdrawal. Information included hospitalizations, ER visits, day
or night clinic stays, outpatient treatment, daily living conditions,
and occupational status. Logistic regressions modeled the proba-
bility of hospitalization vs. no hospitalization for psychiatric and
social reasons, as well as hospitalizations for psychiatric reasons
only, during the DB phase. The models controlled for OL baseline
hospitalizations, OL phase hospitalizations, and time in study.
Results The analysis set included 483 subjects randomized to
PP3M and 512 subjects to PP1M during the DB phase. The odds
of hospitalization for psychiatric/social reasons during 1 year for
PP1Msubjects were 1.16 times the odds of hospitalization for PP3M
subjects (95% CI: 0.70, 1.93, P = 0.56). For psychiatric reasons only,
the odds of hospitalization during 1 year for PP1M subjects were
1.63 times the odds of hospitalization for PP3M subjects (95% CI:
0.88, 3.02, P= 0.12).
Conclusions PP3Mand PP1Mdemonstrated similar trends in hos-
pitalizations throughout the course of the study.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW572
The effects of fluvoxamine on
cognition in patients with
schizophrenia
S.M. Zamir ∗, S.A. Haji Seyed Javadi , Z. Farzaneh Khanshir
Qazvin university of medical sciences, Psychiatry, Qazvin, Iran
∗ Corresponding author.
Introduction Schizophrenia is a severe disease which affects
different aspects of behavior, including cognitive functions. The
most important fields of cognitive disorders in schizophrenia are
working memory, vigilance/attention, learning by oral and visual
memory, argument and resolving, analysis rate and social knowl-
edge.
Aims This studywas designed to assess the effects of fluvoxamine
on cognitive functions of schizophrenic patients.
Method Thirty-six patients with schizophrenia, all male, were
treated with 100mg fluvoxamine and a second generation anti-
psychotic for 4 weeks and before and after treatment, their
cognitive functions were assessed by Wechsler-3 memory scale